TrialClinical cancer research : an official journal of the American Association for Cancer Research2020

Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.

Erika J Lampert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.